Jade Biosciences (JBIO) Common Equity (2020 - 2026)

Jade Biosciences' Common Equity history runs 7 years deep, the most recent figure standing at $296.5 million for Q1 2026.

• Quarterly Common Equity rose 455.0% year-over-year to $296.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $296.5 million (up 455.0% YoY) and the FY2025 annual result came in at $332.5 million, up 810.52% from the prior year.
• Common Equity was $296.5 million for Q1 2026 at Jade Biosciences, down from $332.5 million in the prior quarter.
• Across five years, Common Equity topped out at $332.5 million in Q4 2025 and bottomed at -$83.5 million in Q1 2025.
• A 5-year average of $118.9 million and a median of $126.7 million in 2022 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 34320.03% in 2025, while the deepest fall reached 191.87% in 2025.
• Jade Biosciences' Common Equity stood at $126.7 million in 2022, then declined by 13.64% to $109.5 million in 2023, then plunged by 142.76% to -$46.8 million in 2024, then surged by 810.52% to $332.5 million in 2025, then fell by 10.84% to $296.5 million in 2026.
• Business Quant data shows JBIO's Common Equity at $296.5 million in Q1 2026, $332.5 million in Q4 2025, and $179.3 million in Q3 2025.